Jadenu Tablet, Film Coated
Product Images NDC 0078-0655

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Jadenu (NDC 0078-0655). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Deferasirox Structural Formula. (Jadenu 01)

Deferasirox Structural Formula. (Jadenu 01)
Chemical structure of deferasirox, the active ingredient in Jadenu tablets. The diagram shows the molecular arrangement including hydroxyl groups and aromatic rings characteristic of deferasirox.*
FDA Label Image

Figure 1. Changes In Liver Iron Concentration And Serum Ferritin Following Jadenu (5 30 mg/kg Per Day) In Study 1. (Jadenu 02)

Figure 1.  Changes In Liver Iron Concentration And Serum Ferritin Following Jadenu (5 30 mg/kg Per Day) In Study 1. (Jadenu 02)
A bar chart showing the effect of deferasirox dose (mg/kg/day) on liver iron content and serum ferritin levels. The x-axis lists deferasirox doses of 5, 10, 20, and 30 mg/kg/day with sample sizes noted. The y-axes depict changes in liver iron content (mg Fe/g dry weight) on the left and changes in serum ferritin (mcg/L) on the right. Data are represented with white bars for liver iron content and black bars for serum ferritin, illustrating trends of decreasing levels at higher doses.*
FDA Label Image

Principal Display Panel – Package Label – 90 mg (Jadenu 03)

Principal Display Panel – Package Label – 90 mg (Jadenu 03)
Jadenu 90 mg film-coated tablets label by Novartis Pharmaceuticals Corporation. The label includes the drug name with the active ingredient deferasirox, specifies the strength as 90 mg per tablet, and states that the package contains 30 tablets. The label also includes storage and prescribing information, a barcode, and a notice for pharmacists to dispense with a medication guide.*
FDA Label Image

Principal Display Panel – Package Label – 180 mg (Jadenu 04)

Principal Display Panel – Package Label – 180 mg (Jadenu 04)
Jadenu 180 mg film-coated tablets label showing the active ingredient deferasirox. The label indicates the product is for oral use, supplied by Novartis Pharmaceuticals Corporation. It includes storage instructions, a barcode, and a 30-tablet package count with a pharmacist dispensing note.*
FDA Label Image

Principal Display Panel – Package Label – 360 mg (Jadenu 05)

Principal Display Panel – Package Label – 360 mg (Jadenu 05)
Label for Jadenu (deferasirox) 360 mg film-coated tablets by Novartis Pharmaceuticals Corporation. The package contains 30 tablets and includes directions for pharmacists to dispense with a medication guide. The label shows the NDC code 0078-0656-15 and storage instructions.*
FDA Label Image

Principal Display Panel – Package Label – 90 mg Sprinkle (Jadenu Sprinkle 06)

Principal Display Panel – Package Label – 90 mg Sprinkle (Jadenu Sprinkle 06)
Jadenu Sprinkle 90 mg oral granules carton label for deferasirox by Novartis Pharmaceuticals Corporation. The label includes dosage form and strength, patient instructions for use, storage information, and manufacturer details. The package contains 30 sachets of oral granules.*
FDA Label Image

Principal Display Panel – Package Label – 180 mg Sprinkle (Jadenu Sprinkle 07)

Principal Display Panel – Package Label – 180 mg Sprinkle (Jadenu Sprinkle 07)
Packaging label for Jadenu Sprinkle (deferasirox) oral granules, 180 mg strength. The label includes product name, dosage form as oral granules, and strength prominently on an orange banner. The label indicates the product contains 30 sachets and includes patient instructions for use. The labeler is Novartis Pharmaceuticals Corporation, and storage instructions are provided. The barcode, NDC number 0078-0713-15, and prescribing information notice are also included.*
FDA Label Image

Principal Display Panel – Package Label – 360 mg Sprinkle (Jadenu Sprinkle 08)

Principal Display Panel – Package Label – 360 mg Sprinkle (Jadenu Sprinkle 08)
Packaging label for Jadenu Sprinkle containing deferasirox oral granules, 360 mg strength. The label states the product is by Novartis Pharmaceuticals Corporation and includes patient instructions for use. The package contains 30 sachets, each equivalent to 360 mg deferasirox. The design features white and blue colors with text detailing storage conditions, manufacturer, and barcodes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.